Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3
A1444-040 Trial

### Daclatasvir + Sofosbuvir Trial: Features

**Design**: Randomized, open label, phase 2a, using daclatasvir + sofosbuvir +/- ribavirin in treatment naive or experienced, chronic HCV GT 1-3

**Setting**: United States

**Entry Criteria**
- Chronic HCV Genotype 1, 2, or 3
- Treatment naïve or treatment experienced
- No evidence of cirrhosis

**Patient Groups**
- N = 211 total received treatment
- N = 44 Rx naïve with GT1: DCV+ SOF +/- RBV x 24 weeks
- N = 44 Rx naïve patients with GT 2 or 3: DCV+ SOF +/- RBV x 24 weeks
- N = 123 Rx naïve or experienced with GT 1: DCV+ SOF +/- RBV x 12 weeks

**End-Points**: Primary = SVR12
Daclatasvir + Sofosbuvir +/- Ribavirin for HCV GT 1-3
A1444-040 Design: Treatment-Naïve 24 Week Rx

<table>
<thead>
<tr>
<th>Week</th>
<th>0</th>
<th>12</th>
<th>24</th>
<th>36</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rx Naïve GT 2 or 3</td>
<td>n = 16</td>
<td>SOF × 7 days, then DCV + SOF</td>
<td>SVR12</td>
<td></td>
</tr>
<tr>
<td>n = 14</td>
<td>DCV + SOF</td>
<td>SVR12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n = 14</td>
<td>DCV + SOF + RBV</td>
<td>SVR12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rx Naïve GT 1a/1b</td>
<td>n = 15</td>
<td>SOF × 7 days, then DCV + SOF</td>
<td>SVR12</td>
<td></td>
</tr>
<tr>
<td>n = 14</td>
<td>DCV + SOF</td>
<td>SVR12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n = 15</td>
<td>DCV + SOF + RBV</td>
<td>SVR12</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Drug Dosing
Daclatasvir (DCV): 60 mg once daily
Sofosbuvir (SOF): 400 mg once daily
Ribavirin (RBV): GT1, given weight-based and divided bid (1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg)
Ribavirin (RBV): GT 2,3 (800 mg/day)

Daclatasvir + Sofosbuvir +/- Ribavirin for HCV GT 1-3
Design: GT1 Treatment-Naïve & Experienced 12 Week Rx

<table>
<thead>
<tr>
<th>Week</th>
<th>0</th>
<th>12</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rx Naïve GT 1a/1b n = 82</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n = 41</td>
<td>DCV + SOF</td>
<td>SVR12</td>
<td></td>
</tr>
<tr>
<td>n = 41</td>
<td>DCV + SOF + RBV</td>
<td>SVR12</td>
<td></td>
</tr>
<tr>
<td>Rx Experienced GT 1a/1b n = 41</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n = 21</td>
<td>DCV + SOF</td>
<td>SVR12</td>
<td></td>
</tr>
<tr>
<td>n = 20</td>
<td>DCV + SOF + RBV</td>
<td>SVR12</td>
<td></td>
</tr>
</tbody>
</table>

**Drug Dosing**
- Daclatasvir (DCV): 60 mg once daily
- Sofosbuvir (SOF): 400 mg once daily
- Ribavirin (RBV): GT1, given weight-based and divided bid (1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg)
- Ribavirin (RBV): GT 2,3 (800 mg/day)

Daclatasvir + Sofosbuvir +/- Ribavirin for HCV GT 1-3
A1444-040 Treatment-Naïve 24 Week Rx: Results

<table>
<thead>
<tr>
<th>Week</th>
<th>0</th>
<th>12</th>
<th>24</th>
<th>36</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rx Naïve GT 2 or 3</td>
<td>n = 16</td>
<td>SOF × 7 days, then DCV + SOF</td>
<td>SVR12 = 88%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>n = 14</td>
<td>DCV + SOF</td>
<td>SVR12 = 93%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>n = 14</td>
<td>DCV + SOF + RBV</td>
<td>SVR12 = 86%</td>
<td></td>
</tr>
<tr>
<td>Rx Naïve GT 1a/1b</td>
<td>n = 15</td>
<td>SOF × 7 days, then DCV + SOF</td>
<td>SVR12 = 100%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>n = 14</td>
<td>DCV + SOF</td>
<td>SVR12 = 100%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>n = 15</td>
<td>DCV + SOF + RBV</td>
<td>SVR12 = 100%</td>
<td></td>
</tr>
</tbody>
</table>

Drug Dosing
Daclatasvir (DCV): 60 mg once daily
Sofosbuvir (SOF): 400 mg once daily
Ribavirin (RBV): GT 1, given weight-based and divided bid (1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg)
Ribavirin (RBV): GT 2,3 (800 mg/day)

Daclatasvir + Sofosbuvir +/- Ribavirin for HCV GT 1-3
A1444-040 Treatment-Naïve 24 Week Rx: Results

Patients with SVR12 (%)

<table>
<thead>
<tr>
<th>Treatment-Naïve: GT 2 or 3</th>
<th>Treatment-Naïve: GT 1a or 1b</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOF x 7d DCV + SOF</td>
<td>DCV + SOF</td>
</tr>
<tr>
<td>14/16</td>
<td>15/15</td>
</tr>
<tr>
<td>DCV + SOF</td>
<td>DCV + SOF</td>
</tr>
<tr>
<td>13/14</td>
<td>14/14</td>
</tr>
<tr>
<td>DCV + SOF + RBV</td>
<td>DCV + SOF + RBV</td>
</tr>
<tr>
<td>12/14</td>
<td>15/15</td>
</tr>
</tbody>
</table>

DCV = daclatasvir; SOF = sofosbuvir; RBV = ribavirin

Daclatasvir + Sofosbuvir +/- Ribavirin for HCV GT 1-3
GT1 Treatment-Naïve & Experienced 12 Week Rx: Results

**Rx Naïve**
GT 1a/1b
- n = 82

- n = 41
  - DCV + SOF
  - SVR12 = 100%

- n = 41
  - DCV + SOF + RBV
  - SVR12 = 100%

**Rx Experienced**
GT 1a/1b
- n = 41
  - Prior Boceprevir- or Telaprevir failure

- n = 21
  - DCV + SOF
  - SVR12 = 90%

- n = 20
  - DCV + SOF + RBV
  - SVR12 = 95%

**Drug Dosing**
Daclatasvir (DCV): 60 mg once daily
Sofosbuvir (SOF): 400 mg once daily
Ribavirin (RBV): GT1, given weight-based and divided bid (1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg)
Ribavirin (RBV): GT 2,3 (800 mg/day)

Daclatasvir + Sofosbuvir +/- Ribavirin for HCV GT 1-3
GT1 Treatment-Naïve & Experienced 12 Week Rx: Results

DCV + SOF
DCV + SOF + RBV
DCV + SOF
DCV + SOF + RBV

Patients with SVR12 (%)

Treatment-Naïve: GT 1a or 1b
Treatment-Experienced: GT 1a or 1b

DCV = daclatasvir; SOF = sofosbuvir; RBV = ribavirin

Conclusions: “Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.”
This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

Hepatitis Web Study


Funded by a grant from the Centers for Disease Control and Prevention.